Most Read Articles
Roshini Claire Anthony, one year ago
Earlier age of menarche is significantly linked to a higher risk of gestational diabetes mellitus (GDM) independent of other risk factors, according to a recent study.
one year ago
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Radha Chitale, 2 years ago
Just 5 kg of extra weight following pregnancy in obese women who developed gestational diabetes (GDM) sends their risk of developing type 2 diabetes (T2D) skyrocketing. 
one year ago
High maternal BMI before pregnancy is linked with elevated oxidative stress in the newborn, as reported in a study.

Denosumab in Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture

2 years ago
Recently, MIMS Doctor sat down with Associate Professor Dr Sabarul Afian Mokhtar to get his perspectives on the use of monoclonal antibody for the treatment of postmenopausal osteoporosis (PO) and also important learning from the International Osteoporosis Foundation (IOF) Regionals 5th Asia-Pacific Osteoporosis Meeting. Highlights from the interview are presented here.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, one year ago
Earlier age of menarche is significantly linked to a higher risk of gestational diabetes mellitus (GDM) independent of other risk factors, according to a recent study.
one year ago
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Radha Chitale, 2 years ago
Just 5 kg of extra weight following pregnancy in obese women who developed gestational diabetes (GDM) sends their risk of developing type 2 diabetes (T2D) skyrocketing. 
one year ago
High maternal BMI before pregnancy is linked with elevated oxidative stress in the newborn, as reported in a study.